GSK CEO Emma Walmsley said the sector would need to wait to see who is appointed in key roles in the Trump administration to ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...

At the Financial Times (FT) Global Pharma and Biotech Summit in London on 6 November, GSK CEO Emma Walmsley addressed these concerns and underscored the critical role of the US in GSK’s operations.

I think elections are like pregnancy. … Everyone puts all of the energy into D-day – the birth. We’ve had the gender reveal, but what really, really matters is what happens now and the path ahead.” ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

GSK market cap is currently £55.9B and has a P/E ratio of 22.22. Based on the recent corporate insider activity of 333 insiders, corporate insider sentiment is positive on the stock. This means that ...

GSK has received approval for its vaccine, AREXVY, in Canada to prevent LRTD caused by RSV in adults aged 50 to 59 years.

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesityCompleted $238.3 million initial public offering and ...

By enhancing DEI strategies, UK firms can set themselves apart, fostering inclusivity that drives growth – Reshma Sheikh ...

Speculation is mounting GlaxoSmithKline's CEO Emma Walmsley may pay the price for the company’s lacklustre performance, after the dreaded activist investor Elliott Management built a stake in ...

But Sky News reports that shareholders want the incoming CEO to have a reduced pay package compared with her predecessor. Previously head of GSK’s consumer health division, Walmsley joined the ...